AbbVie records $744M IPR&D expense in Q1; cuts adjusted EPS guidance by $0.41

AbbVie Inc.

2026-Q1 EPS reported $0.39 vs consensus $2.65 ▼ miss (-85.3%)

Q1 2026 includes $744M pre-tax acquired IPR&D and milestones expense, reducing EPS by $0.41.
Updated Q1 adjusted EPS guidance: $2.56-$2.60 (from $2.97-$3.01, excluding Q1 IPR&D).
Full-year 2026 adjusted EPS guidance lowered to $13.96-$14.16 (from $14.37-$14.57).
Company states future IPR&D milestones cannot be reliably forecasted; guidance excludes them beyond Q1.
Adjusted diluted EPS guidance now includes impact of Q1 expense; prior range excluded it.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AbbVie Inc. reported quarter ended March 31, 2026 results: EPS $2.56 - $2.60. Guidance lowered.

Period: quarter ended March 31, 2026
EPS: $2.56 - $2.60
Guidance: lowered
Result: guidance update

Exact text from the filing

AbbVie’s first quarter 2026 adjusted diluted earnings per share guidance range, including the impact of first quarter 2026 acquired IPR&D and milestones expense, is $2.56 - $2.60.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AbbVie Inc. reported full-year ended December 31, 2026 results: EPS $13.96 - $14.16. Guidance lowered.

Period: full-year ended December 31, 2026
EPS: $13.96 - $14.16
Guidance: lowered
Result: guidance update

Exact text from the filing

AbbVie’s full-year 2026 adjusted diluted earnings per share guidance range, including the impact of first quarter 2026 acquired IPR&D and milestones expense, is $13.96 - $14.16.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001551152-26-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.